Table 2.
Demographics and clinical features of the patients diagnosed with Pneumocystis jiroveci pneumonia in the Olmsted Country Inflammatory Bowel Disease cohort (1970 – 2011), with follow-up through February 2016
| Case 1 | Case 2 | Case 3 | |
|---|---|---|---|
|
|
|||
| Age, years | 63 | 74 | 78 |
| Sex | Male | Male | Male |
| IBD subtype | CD | UC | UC |
| Duration of IBD at time of PJP diagnosis, years | 9.2 | 6.2 | 5.2 |
| Relevant co-morbidities | COPD | None | Bronchiectasis |
| Immunosuppression | 4.2 years of infliximab and methotrexate | 1 month of infliximab and prednisone | 3.7 years of azathioprine |
| PJP prophylaxis | No | No | No |
| Treatment | TMP/SMX | TMP/SMX, prednisone | TMP/SMX |
| Responded to Treatment | Yes | Yes | Yes |
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; COPD, chronic obstructive pulmonary disease; TMP/SMX, trimethoprim/sulfamethoxazole